News Helus shares slide on psychedelic readout in depression Helus has revealed data from a phase 3 trial of HLP003 that showed evidence of efficacy in depression, although its shares fell on safety concerns.
News J&J cuts $3.3bn deal to buy eye drug developer Ollin Johnson & Johnson has agreed to buy Texas biotech Ollin Biosciences for $2.2bn upfront, adding a keenly anticipated therapy for ophthalmic disorders.
News Lilly strikes again, buying Calytrix in $1.5bn deal Eli Lilly has added yet another name to its list of M&A deals this year after agreeing to buy blood disorder specialist Calytrix Bio for up to $1.5bn.
News Gazyva is first FDA-cleared drug for rare disease pMN Patients in the US with primary membranous nephropathy have a first approved drug, after the FDA cleared Roche's Gazyva for the rare kidney disorder.
News AZ's Alexion extends gMG options with two Klygefa approvals AstraZeneca's Alexion unit has won approval in the US and EU for Klygefa, billed as a future blockbuster, for generalised myasthenia gravis (gMG).
News China overtakes Europe in healthcare investing sentiment China has overtaken Europe as the preferred location for healthcare investing, according to Jefferies' Healthcare Temperature Check report.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.